Off-label Use of Balloon-Expandable Transcatheter Valves to Treat Pure Aortic Regurgitation

Transcatheter aortic valve implantation (TAVI) in native pure aortic regurgitation (AR) with off-label use of balloon expandable valves (BEV) has been reported. However, there are scant data regarding optimal oversizing and its safety and our study assessed BEV oversizing and outcomes of TAVI. Thirteen consecutive tricuspid aortic valve patients undergoing transfemoral TAVIs for pure AR with Sapien BEV at our centre between 2019 and 2023 (69.2% males, mean age 80.8 years, STS 4.0%) were divided into small annulus group ( ≤618mm2, SA) where ≥20% oversizing is achievable based on published data on BEV overexpansion, and larger annulus group (LA,>618mm2).

Source: The American Journal of Cardiology - April 22, 2024 Category: Cardiology Authors: Mateusz Orzalkiewicz, Marco Foroni, Francesco Chietera, Francesco Bendandi, Alessandro Mazzapicchi, Antonio Giulio Bruno, Gabriele Ghetti, Nevio Taglieri, Cinzia Marrozzini, Nazzareno Gali è, Tullio Palmerini, Francesco Saia Tags: Brief report Source Type: research